Vion Submits Laromustine For Use In Niche Population
This article was originally published in The Pink Sheet Daily
Vion takes the quickest path to market for laromustine, now Onrigin, by submitting an NDA for use in elderly patients with poor prognosis.
You may also be interested in...
Company concedes it could run out of cash in 2009 if cancer drug is not commercialized.
Suspension is a “hiccup” but development of the alkylating agent for adult myelogenous leukemia will move forward, Vion CEO Kessman states.
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.